CP23 | 30652-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: CP23
• 英文别名: 3-Hydroxy-2-methyl-1-(1'-methylethyl)pyrid-4-one；1-isopropyl-3-hydroxy-2-methylpyrid-4-one；4(1H)-Pyridinone, 3-hydroxy-2-methyl-1-(1-methylethyl)-；3-hydroxy-2-methyl-1-propan-2-ylpyridin-4-one
• CAS: 30652-14-3
• 化学式: C₉H₁₃NO₂
• 分子量: 167.208
• InChiKey: UPFWEAFOAQNIHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  麦芽醇 在 盐酸 、 palladium 10% on activated carbon 、 氢气 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 92.0~105.0 ℃ 、400.01 kPa 条件下， 反应 44.0h， 生成 CP23
  参考文献：
  名称：

  Synthesis, Antiplasmodial Activity, and β-Hematin Inhibition of Hydroxypyridone–Chloroquine Hybrids

  摘要：

  A series of noncytotoxic 4-aminoquinoline-3-hydroxypyridin-4-one hybrids were synthesized on the basis of a synergistic in vitro combination of a precursor N-alkyl-3-hydroxypyridin-4-one with chloroquine (CQ) and tested in vitro against CO resistant (K1 and W2). an sensitive (3D7) strains of Plasmodium falciparum. In vitro antiplasmodial activity of the precursors was negated by blocking the chelator moiety Via complexation with gallium(III) or benzyl protection. None of the precursors inhibited beta-hematin formation. Most hybrids were more potent inhibitors of beta-hematin formation than CQ and a correlation between antiplasmodial activity and inhibition of beta-hematin formation was observed. Potent hybrids against K1, 3D7, and W2, respectively, were 8c (0.13, 0.004, and 0.1 mu M); 8d (0.08, 0.01, and 0.02 mu M); and 7g (0.07, 0.03, and 0.08 mu M).

  DOI：

  10.1021/ml4001084

文献信息

• Technetium-99m complexes with N-substituted 3-hydroxy-4-pyridinones
  申请人：The Du Pont Merck Pharmaceutical Company

  公开号：US05336482A1

  公开（公告）日：1994-08-09

  Disclosed are cationic complexes of Tc-99m and ligands having the structure: ##STR1## wherein: R.sup.1 is hydrogen or is selected from the group consisting of C.sub.1 to C.sub.20 alkyl; C.sub.3 to C.sub.12 cycloalkyl; C.sub.7 to C.sub.24 aralkyl; C.sub.2 to C.sub.16 alkyl ethers, thioethers, ketones or esters; C.sub.7 to C.sub.27 aralkyl ethers; R.sup.2 is hydrogen or is a C.sub.1 to C.sub.4 lower alkyl radical selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

  本发明揭示了Tc-99m阳离子配合物和具有以下结构的配体：##STR1## 其中：R.sup.1是氢或选择自C.sub.1至C.sub.20烷基；C.sub.3至C.sub.12环烷基；C.sub.7至C.sub.24芳基烷基；C.sub.2至C.sub.16烷基醚，硫醚，酮或酯；C.sub.7至C.sub.27芳基烷基醚；R.sup.2是氢或是选择自甲基，乙基，丙基，异丙基，丁基，异丁基，仲丁基和叔丁基的C.sub.1至C.sub.4低烷基基团。
• Pharmaceutical compositions containing a complex of iron with N-substituted 3-hydroxypyrid-2-one or -4-one derivatives
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0094149A2

  公开（公告）日：1983-11-16

  Pharmaceutical compositions containing an iron complex of a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic hydrocarbon group and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are also replaced by an aliphatic hydrocarbon group, are of value for the treatment of iron deficiency anaemia.

  含有 3-羟基吡啶-2-酮或 3-羟基吡啶-4-酮铁络合物的药物组合物，其中氮原子上的氢原子被脂肪族烃基取代，环碳原子上的一个或多个氢原子也被脂肪族烃基取代，具有治疗缺铁性贫血症的价值。
• Pharmaceutical compositions
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0145228A1

  公开（公告）日：1985-06-19

  Zinc (11) complexes in which at least one ligand is provided by a compound being: (1) 3-hydroxy-4-pyrone or a 3-hydroxy-4-pyrone in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic hydrocarbon group of 1 to 6 carbon atoms; or (2) a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionisable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group; are of value in medicine, particularly in the systemic treatment of zinc depletion. Mixtures of these zinc complexes with the metal-free compound(s) providing the ligands contained therein and with iron (III) complexes containing ligands of types (1) and (2) are also of value.

  锌(11)配合物，其中至少一种配体由以下化合物提供： (1) 3-羟基-4-吡喃酮或 3-羟基-4-吡喃酮，其中与环碳原子相连的一个或多个氢原子被 1 至 6 个碳原子的脂肪族烃基取代；或 (2) 3-羟基吡啶-2-酮或 3-羟基吡啶-4-酮，其中与氮原子相连的氢原子被脂族酰基、1 至 6 个碳原子的脂族烃基取代，或被选自脂族酰基、烷氧基、脂族胺、脂族酰胺、羧基的一个或一个以上取代基取代（可电离基团除外）的脂族烃基取代、脂肪族酰胺、羧基、脂肪族酯、卤素、羟基和砜基，可选地，其中一个或多个与环碳原子相连的氢原子被上述取代基之一、1 至 6 个碳原子的脂肪族烃基或被烷氧基、脂肪族酯、卤素或羟基取代的脂肪族烃基所取代；具有医药价值，特别是在系统治疗锌缺乏症方面。这些锌络合物与提供其中所含配体的无金属化合物的混合物，以及与含有(1)和(2)型配体的铁(III)络合物的混合物也很有价值。
• Iron 3-hydroxypyrone or 3-hydroxypyridone complexes and pharmaceutical compositions containing them
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0159194A2

  公开（公告）日：1985-10-23

  Iron complexes comprising a ferric cation in combination with at least two different ligands, at least one of which is provided by a compound being: (1) 3-hydroxy-4-pyrone or a 3-hydroxy-4-pyrone in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic hydrocarbon group of 1 to 6 carbon atoms; or (2) a 3-hydroxyprid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is . replaced by an aliphtic acyl group, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphtic hydrocarbon group substituted by one or more substituents selected from aliphatic acyl, alkoxy, aliphatic amide, aliphatic ester, halogen and hydroxy groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group; the charge on the ferric cation being neutralised by the charge on the ligands covalently bound thereto; are of value in medicine, particularly in the treatment of iron deficiency anaemia.

  铁络合物，包括一个铁阳离子与至少两个不同配体的组合，其中至少一个配体由以下化合物提供： (1) 3-羟基-4-吡喃酮或 3-羟基-4-吡喃酮，其中与环碳原子相连的一个或多个氢原子被 1 至 6 个碳原子的脂族烃基取代；或 (2) 3-羟基-2-吡啶酮或 3-羟基-4-吡啶酮，其中与氮原子相连的氢原子被.被脂族酰基、1 至 6 个碳原子的脂族烃基或 1 至 6 个碳原子的脂族烃基取代，或被一个或多个选自脂族酰基、烷氧基、脂族酰胺、脂族酯的取代基取代的脂族烃基取代、卤素和羟基基团取代的脂族烃基，或由 1 至 6 个碳原子的脂族烃基取代的脂族烃基，或由烷氧基、脂族酯、卤素或羟基基团取代的脂族烃基；铁阳离子上的电荷被与其共价结合的配体上的电荷所中和；这些物质在医学上，特别是在治疗缺铁性贫血症方面具有重要价值。
• Pharmaceutical compositions containing N-substituted-3-hydroxypyrid-2-one or -4-one derivatives
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0093498B1

  公开（公告）日：1986-11-26